Imad A. Haidar Ahmad Email & Phone Number

Thousand Oaks, California, United States

Rahway, New Jersey, United States

• Leading a team of scientists at different levels to enable purification at various scales (µg-kg) using various separation techniques: RPLC, NPLC, SFC, IEX, SEC, 2D-LC at analytical scale and preparative scale, salt/ion exchange, and flash chromatography.• Develop capabilities for purifying highly potent compounds.• Partner with colleagues in process chemistry, discovery, analytical DS and DP, and manufacturing to enable development of analytical methods, purification of API, isolation of target impurities, API salt/ion exchange, etc.• Introduce new and advanced capabilities to isolate target compounds from small and large molecule complex matrices.• Develop goals/priorities for multiscale separation team (pipeline deliveries, collaboration with partners, align with senior leadership, build a strong and collaborative culture, invest in growth of employees, etc.)• Lead departmental initiatives to increase productivity, implement the use of digital tools, foster a culture of scientific excellence• Increased productivity of team by 2X in the last 12 months. This was made possible by introducing new capabilities, increased automation, team cross-training, work prioritization, among others.

Rahway, Nj

Method Screening & Purification group• Method Development SME: for methods used at analytical and preparative scale. Built workflows for developing methods for challenging separation including: buffer selection, column screening and selection, optimum column/mobile phase selection, method optimization, robustness evaluation, and method transfer. • Chromatography modeling – SME for global Merck (Integrated software-assisted method development as part of method development to enable challenging separation and robustness evaluation.). Modeling used to optimize (chiral-RPLC, achiral-RPLC, HIC, IEX, 2D-LC, etc.). Extended the reach of modeling to complex modalities (proteins, mAbs, vaccines, etc.). Published 10 papers on this topic, several in Analytical Chemistry with front covers. • Impurity isolation – SME for challenging impurity isolation Development of robust analytical methods. Built workflows for chiral and achiral LC screening systems.• API purification – up to kg scale (Enabled purification of API drug substance at gram and kilogram levels. Material enabled clinical trials, candidate selection, crystallization, formulation, etc.)• Multi-dimensional LC for analytical and purification scale to investigate drug purity, method development, mass balance issues, MS determination with unfriendly buffers column selection, investigations, audits, and troubleshooting, impurity profiling of multi-API drugs. Introduced 2D-LC with enrichment capabilities for impurity isolation at microscale level• SME for development and optimization of charged aerosol detection methods which include optimization of chromatographic parameters and Charged Aerosol Detector (CAD) setting to enable best performance of methods in early and late-stage phases. (Several papers published on this topic)• Scientific Supervisor: Mentoring several senior scientist, scientist, contractors, postdocs, and summer interns in the MSP group

Rahway, Nj

• Lead method development and optimization of various programs.• Analytical representative and lead for pipeline programs. • SME for method optimization using computer-assisted software modeling.• Enabled pipeline programs through testing and analysis under GMP/GLP environment.• Established methods and algorithms for detection and quantitation of compounds with poor or no chromophore using (CAD).• SME for HPLC/UHPLC troubleshooting

San Carlos

• Lead method development/optimization of inhalation drug product programs (Analytical lead)• SME for analytical method development for global Novartis. Built workflow for method development which includes columns and buffers selection, optimum column/mobile phase determination, method optimization, robustness evaluation, and method transfer. • Enabled analytical method development and analysis of drugs at various stages of development from discovery to post approval. GMP experience includes validation of early phase and late phase methods along with supporting analytical packages for NDA submissions. • SME for development of methods for analytes with no-chromophores (including the optimization of CAD settings)• Validation of analytical methods for early and late-stage programs.• Adapting new tools for developing and analysis of challenging separations (CAD, multi-dimension LC, multi-detector LC)• Established methods and algorithms for detection and quantitation of compounds with poor or no chromophore using (CAD).• SME for cleaning validation including GMP testing. Resolved critical issues and discrepancies at manufacturing site related to successful development and validation of cleaning validation for large and small molecules. Approach adapted at several sites withing Novartis. (Several papers published on this topic)• Co-lead of analytical network for global Novartis.• Extensive experience in State-of-the-art UHPLC Instrument evaluation from ThermoFisher, Agilent, Waters, and Agilent. Lead instrument evaluation for state-of-the-art UHPLC instruments which fits the need for method development. (Published a review article comparing and evaluating the performance of these UHPLC systems).

San Carlos, Ca

San Carlos, Ca

Greater Minneapolis-St. Paul Area

Postdoctoral researcher with Professor Peter Carr

Postdoctoral Studies, Analytical Chemistry

Phd And Masters Degree

Maitraise, Chemistry